I don't know that the criteria they used in the paper to pick the healthiest and youngest patients is similar to what NWBO used for the DCVAX Phase 3 Johnni. I suspect it is not. This topic has been brought up often on this board and always seem to end concluding they did not cherry pick the patients. Here is a link to a post from AVII77 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163568792 You will see that out of the 1599 screened and the 1268 that rejected included things like: 306 Not GBM 201 Insufficient Tumor Lystate 61 Leukopheresis Unsuccessful ect . . .
Even if one was to assume they did cherry pick the patients look at the table below from the paper you sent me. It has 2 year survival at 33.3 % and 5 year at 10.9% From the blinded data we have for DCVAX PH-3 https://nwbio.com/updated-interim-data-from-phase-3-trial-of-dcvax-l-for-glioblastoma/ Survival at 3 years is 28.2% (similar to the 33.3% at 2 years for the cherry picked patients) Survival at 3 years for 41.1% (methylated) This is all patients so I think we will still be better than the cherry picked patients in the paper. We have not see the 5 year results for DCVAX yet but we do know that survival flattened out. Thanks for sending.
Men who are occupied in the restoration of health to other men, by the joint exertion of skill and humanity, are above all the great of the earth. They even partake of divinity, since to preserve and renew is almost as noble as to create.